iAnthus closes on acquisition of New Jersey medical cannabis operation

What’s the right revenue per square foot? What’s a realistic business outlook for cultivators? Get realistic market forecasts, state-by-state insights and benchmarks. Get the 2023 Factbook.

Multistate operator iAnthus said Thursday it closed on the acquisition of a 100% equity interest in MPX New Jersey, a medical cannabis company in the state.

The deal helps pave the way for iAnthus, which has offices in Toronto and New York, to take advantage of New Jersey’s forthcoming recreational marijuana market.

MJBizFactbook projects the market will reach $2 billion in annual sales by the fourth full year.

New Jersey regulators approved the acquisition on Jan. 7, according to an iAnthus news release.

Control of the lucrative marijuana operation had been the subject of a legal proceeding.

Thursday’s news release doesn’t mention that case, but an iAnthus regulatory filing states that the legal matter was resolved and closed in March 2021.

In February 2021, iAnthus raised $11 million from a debt offering with the intent to make significant improvements at the MPX cultivation and processing facility in Pleasantville, New Jersey.

Apply to speak at MJBizCon 2023

Think you’ve got a great story, insights, or best practices to share about your cannabis business? We want to hear from you!

The MJBizCon team is now accepting speaker applications for the 2023 event in Las Vegas.

We are looking for engaging industry leaders from all sectors of the cannabis industry, whether you run a multi-state operation or a mom-and-pop business.

Apply to speak at MJBizCon today – The speaker application portal closes May 5!

The company said it also plans to open a dispensary in Atlantic City in the next few months.

As disclosed in a December news release, iAnthus still needs regulatory approvals in several states for a previously announced financial restructuring and recapitalization plan.